EUCTR2004-001321-25-IT进行中（未招募）不适用
A prospective, open label, monocenter trial to evaluate the interaction between the Platelia Aspergillus ELISA test and the administration of piperacillin/tazobactam.
WYETH LEDERLE0 个研究点开始时间: 2004年7月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
招募中
4 期
Intravitreal Aflibercept for the Treatment of Treatment Resistant Macular Oedema secondary to Retinal Vein Occlusionsmacular oedema secondary to retinal vein occlusionACTRN12617001487303A/Prof Andrew Chang50
招募中
1 期
Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor therapyMedDRA version: 20.1Level: LLTClassification code: 10079841Term: Atypical hemolytic uremic syndrome Class: 10005329Atypical hemolytic uremic syndromeCTIS2023-508840-22-00ovartis Pharma AG44
进行中（未招募）
1 期
Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor therapyMedDRA version: 20.1Level: LLTClassification code 10079841Term: Atypical hemolytic uremic syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersatypical hemolytic uremic syndromeEUCTR2020-005186-13-SKovartis Pharma AG50
进行中（未招募）
1 期
Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor therapyMedDRA version: 20.1Level: LLTClassification code 10079841Term: Atypical hemolytic uremic syndromeSystem Organ Class: 100000004851atypical hemolytic uremic syndromeEUCTR2020-005186-13-SIovartis Pharma AG50
进行中（未招募）
1 期
Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor therapyatypical hemolytic uremic syndromeEUCTR2020-005186-13-ATovartis Pharma AG50